Abstract
Sesquiterpene lactones (SLs) are biologically active compounds found in various medicinal plants. Although the compounds are reported to possess numerous biological activities, but the most important is their immunoregulatory role in inflammatory cells. This is because 1) over-activation of inflammatory cells secretes a large amount of different pro-inflammatory mediators such as cytokines, nitric oxide (NO) and prostaglandin (PG)E2 and 2) SLs can modulate these phenomena effectively through inhibiting the activation pathway of nuclear factor (NF)-κB via the reactivity of some functional groups in SLs such as α-methylene-γ- lactone. This review, therefore, discusses in detail the molecular mechanism and structural features of SLs in blocking NF-κB activation with a general introduction of NF-κB and proposes the possibility that SLs can be developed pharmaceutically useful drugs against NF-κB-mediated diseases and that they can be chemically modified to improve their anti-NF-κB efficacy.
Keywords: Sesquiterpene lactones, NF-κB, I-κB, cytokines, inflammatory mediators, structure-activity relationship study
Current Enzyme Inhibition
Title: Sesquiterpene Lactones as a Potent Class of NF-κB Activation Inhibitors
Volume: 2 Issue: 4
Author(s): Jae Youl Cho
Affiliation:
Keywords: Sesquiterpene lactones, NF-κB, I-κB, cytokines, inflammatory mediators, structure-activity relationship study
Abstract: Sesquiterpene lactones (SLs) are biologically active compounds found in various medicinal plants. Although the compounds are reported to possess numerous biological activities, but the most important is their immunoregulatory role in inflammatory cells. This is because 1) over-activation of inflammatory cells secretes a large amount of different pro-inflammatory mediators such as cytokines, nitric oxide (NO) and prostaglandin (PG)E2 and 2) SLs can modulate these phenomena effectively through inhibiting the activation pathway of nuclear factor (NF)-κB via the reactivity of some functional groups in SLs such as α-methylene-γ- lactone. This review, therefore, discusses in detail the molecular mechanism and structural features of SLs in blocking NF-κB activation with a general introduction of NF-κB and proposes the possibility that SLs can be developed pharmaceutically useful drugs against NF-κB-mediated diseases and that they can be chemically modified to improve their anti-NF-κB efficacy.
Export Options
About this article
Cite this article as:
Youl Cho Jae, Sesquiterpene Lactones as a Potent Class of NF-κB Activation Inhibitors, Current Enzyme Inhibition 2006; 2 (4) . https://dx.doi.org/10.2174/157340806778699299
DOI https://dx.doi.org/10.2174/157340806778699299 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kinase Inhibitors in Multitargeted Cancer Therapy
Current Medicinal Chemistry Genipin Inhibits the Induction of Inducible Nitric Oxide Synthase Through the Inhibition of NF-κB Activation in Rat Hepatocytes
Drug Metabolism Letters Follistatin-like 1 in Cardiovascular Disease and Inflammation
Mini-Reviews in Medicinal Chemistry Label-Free Mass Spectrometry-Based Plasma Proteomics Identified LY6D, DSC3, CDSN, SERPINB12, and SLURP1 as Novel Protein Biomarkers For Pulmonary Tuberculosis
Current Proteomics Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design Effects of Exercise on Vascular Toxicity Associated with Breast Cancer Treatment: A Narrative Review
Current Vascular Pharmacology Dry Eye Disease: Present Challenges in the Management and Future Trends
Current Pharmaceutical Design Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases
Current Medicinal Chemistry Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene
Current Clinical Pharmacology Medicinal Chemistry of Drugs with Active Metabolites Following Conjugation
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member:
Current Tissue Engineering (Discontinued) Cyclooxygenase and Atherosclerosis: A Smoking Area
Current Pharmaceutical Design Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry Emerging Therapeutic Agents for Cervical Cancer
Recent Patents on Anti-Cancer Drug Discovery First and Second Generations of COX-2 Selective Inhibitors
Mini-Reviews in Medicinal Chemistry Immunomodulatory Activity of Astragalus, Ginseng and Echinacea: From Keith Block and Mark Mead to Today, Have We Moved On?
Current Immunology Reviews (Discontinued) Management of NSAID/Aspirin-Induced Small Intestinal Damage by GI-Sparing NSAIDs, Anti-Ulcer Drugs and Food Constituents
Current Medicinal Chemistry Tetherin/BST-2: Restriction Factor or Immunomodulator?
Current HIV Research Tumor Initiating Cells
Current Pharmaceutical Biotechnology